Phibro Animal Health Corporatio PAHC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
69/100
Moderate

About Phibro Animal Health Corporatio

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and … Full PAHC analysis →

Competitive advantage assessment

Key strengths

  • ROIC Sustainably Above Peers ROIC at 90.2th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.96), demonstrating pricing resilience across cycles.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
69

Where PAHC ranks in Drug Manufacturers - Specialty & Generic

Phibro Animal Health Corporatio ranks #13 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 14%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near PAHC in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
9 Collegium Pharmaceutical, Inc. COLL 73/100 Moderate
10 Lantheus Holdings, Inc. LNTH 73/100 Moderate
11 Ironwood Pharmaceuticals, Inc. IRWD 71/100 Moderate
12 ANI Pharmaceuticals, Inc. ANIP 69/100 Moderate
13 Phibro Animal Health Corporatio PAHC 69/100 Moderate
14 Bausch Health Companies Inc. BHC 68/100 Moderate
15 Amneal Pharmaceuticals, Inc. AMRX 68/100 Moderate
16 Dr. Reddy's Laboratories Ltd RDY 67/100 Moderate
17 Akebia Therapeutics, Inc. AKBA 67/100 Moderate

See every Pharma / Mature Biotech company ranked by moat score →

How PAHC scores on the Corporate Default defenses

Pricing Power

Score 69 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 84 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 66 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 87 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 57 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 47 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding PAHC's moat

What is Phibro Animal Health Corporatio's moat score?

Phibro Animal Health Corporatio (PAHC) scores 69 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #13 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 14%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Capital Efficiency (87/100) and its weakest is Scale & Market Position (47/100).

How does Phibro Animal Health Corporatio compare with other Drug Manufacturers - Specialty & Generic companies?

Phibro Animal Health Corporatio ranks #13 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are ANI Pharmaceuticals, Inc. (ANIP) at 69 just above it and Bausch Health Companies Inc. (BHC) at 68 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Phibro Animal Health Corporatio scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Phibro Animal Health Corporatio?

The Corporate Default template measures 6 defenses, and PAHC scores: Pricing Power (69), Cost Advantage (84), Customer Stickiness (66), Capital Efficiency (87), Resilience (57), Scale & Market Position (47). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000